Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

It’s a good day to be the pharmaceutical giant Eli Lilly. Right now, Eli Lilly appears to be the leader in the GLP-1 race amid multiple difficult headwinds for Novo Nordisk. As of this writing, Novo ...

Feb 23 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, ...

UPPER MACUNGIE TWP., Pa. — Pharmaceutical giant Eli Lilly and Company is building a manufacturing campus in the Lehigh Valley, a multi-billion-dollar project that promises to create hundreds of new ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...

Rick is a Wall Street Journal best-selling author with over 20 years of experience trading stocks and options. The most authoritative publications, including Good Morning America, Washington Post, ...

Novo Nordisk shares sank after the Danish drugmaker suffered a setback in its battle with Eli Lilly to dominate the market for weight-loss drugs.